Literature DB >> 26339357

Methylprednisolone suppresses the Wnt signaling pathway in chronic lymphocytic leukemia cell line MEC-1 regulated by LEF-1 expression.

Qing-Min Yao1, Pei-Pei Li1, Shu-Mei Liang2, Kang Lu1, Xiao-Juan Zhu1, Yan-Xia Liu1, Feng Zhang1, Ting Yuan1, Xin Wang1.   

Abstract

High dose methylprednisolone (HDMP) has been an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia (CLL), while little is known about the exact mechanisms implicated in glucocorticoid-induced cell death. To explore the mechanism of glucocorticoid-induced cell death, we investigated the effect of HDMP on canonical Wnt signaling which emerged as a key pathway implicated in the pathogenesis of CLL. In this study, the human CLL cell line MEC-1 was incubated with various concentrations of methylprednisolone. Cell proliferation activity was detected by CCK8 assay, the apoptotic effect was evaluated by TUNEL assay. Western blot was used to detect active-caspase 3, and the key proteins in Wnt signaling pathway (LEF-1, β-catenin). RT-PCR was performed to assess the mRNA levels of β-catenin, LEF-1, c-myc and cyclin D1. We observed that high concentration of methylprednisolone could suppress the proliferation activity of MEC-1 cells, promote the relative expression of active-caspase 3, and induce apoptotic cell death. Furthermore, methylprednisolone could inhibit LEF-1 protein expression, consequently down-regulate mRNA levels of c-myc and cyclin D1, but could not affect the transcription level of β-catenin and LEF-1 mRNA. The results of this study indicate that methylprednisolone can suppress Wnt signaling pathway by down-regulating LEF-1 protein expression, indicating a novel mechanism for HDMP therapy in CLL.

Entities:  

Keywords:  LEF-1; Methylprednisolone; chronic lymphocytic leukemia; wnt signaling pathway; β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26339357      PMCID: PMC4555685     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  31 in total

1.  Glucocorticoid-dependent transdifferentiation of pancreatic progenitor cells into hepatocytes is dependent on transient suppression of WNT signalling.

Authors:  Karen Wallace; Carylyn J Marek; Stefan Hoppler; Matthew C Wright
Journal:  J Cell Sci       Date:  2010-05-25       Impact factor: 5.285

2.  Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia.

Authors:  Ali Memarian; Mohammad Hojjat-Farsangi; Hossein Asgarian-Omran; Vahid Younesi; Mahmood Jeddi-Tehrani; Ramazan Ali Sharifian; Jalal Khoshnoodi; Seyed Mohsen Razavi; Hodjatallah Rabbani; Fazel Shokri
Journal:  Leuk Lymphoma       Date:  2009-12

3.  LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.

Authors:  Albert Gutierrez; Renee C Tschumper; Xiaosheng Wu; Tait D Shanafelt; Jeanette Eckel-Passow; Paul M Huddleston; Susan L Slager; Neil E Kay; Diane F Jelinek
Journal:  Blood       Date:  2010-07-01       Impact factor: 22.113

Review 4.  Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more.

Authors:  Jonathan D Turner; Simone R Alt; Lei Cao; Sara Vernocchi; Slavena Trifonova; Nadia Battello; Claude P Muller
Journal:  Biochem Pharmacol       Date:  2010-07-01       Impact factor: 5.858

5.  Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.

Authors:  Rajesh Kumar Gandhirajan; Peter Anton Staib; Katharina Minke; Iris Gehrke; Günther Plickert; Axel Schlösser; Esther Katharina Schmitt; Michael Hallek; Karl-Anton Kreuzer
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

6.  Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.

Authors:  Jerina Boelens; Sofie Lust; Femke Van Bockstaele; Mireille Van Gele; Ann Janssens; Lara Derycke; Barbara Vanhoecke; Jan Philippé; Marc Bracke; Fritz Offner
Journal:  Leuk Res       Date:  2009-03-17       Impact factor: 3.156

7.  Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features.

Authors:  Deborah A Bowen; Timothy G Call; Greg D Jenkins; Clive S Zent; Susan M Schwager; Daniel L Van Dyke; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Leuk Lymphoma       Date:  2007-12

8.  Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia.

Authors:  J E Castro; J D Sandoval-Sus; J Bole; L Rassenti; T J Kipps
Journal:  Leukemia       Date:  2008-08-28       Impact factor: 11.528

Review 9.  Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia.

Authors:  Jiezhong Chen; Nigel A J McMillan
Journal:  Cancer Biol Ther       Date:  2007-11-03       Impact factor: 4.742

10.  Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.

Authors:  J E Castro; D F James; J D Sandoval-Sus; S Jain; J Bole; L Rassenti; T J Kipps
Journal:  Leukemia       Date:  2009-08-20       Impact factor: 11.528

View more
  3 in total

Review 1.  Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies.

Authors:  Blanca Scheijen
Journal:  Cancer Drug Resist       Date:  2019-09-19

2.  Identification of Drug-Disease Associations Using a Random Walk with Restart Method and Supervised Learning.

Authors:  Xiaoqing Liu; Wenjing Yi; Baohang Xi; Qi Dai
Journal:  Comput Math Methods Med       Date:  2022-10-10       Impact factor: 2.809

Review 3.  Emerging Role and Therapeutic Implication of Wnt Signaling Pathways in Autoimmune Diseases.

Authors:  Juan Shi; Shuhong Chi; Jing Xue; Jiali Yang; Feng Li; Xiaoming Liu
Journal:  J Immunol Res       Date:  2016-03-27       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.